Table 4.

Characteristics of Responding Patients.

	Patient 1	Patient 2	Patient 3
Age	63	25	77
Gender	Male	Female	Female
ECOG Performance Status	2	1	1
Diagnosis	Secondary AML from CMML	Primary AML	Secondary AML from MDS
Cytogenetics	46,XY,del(6)(q13q25)[2]; 47,sl,+21[2]; 46,XY[16]	Unknown	46,XX[20]
Prior Lines of Therapy (Last Therapy)	4 (cytarabine)	5 (clofarabine)	2 (clinical trial)
Dose of Lurbinectedin	5 mg (D1, D8)	7 mg (D1, D8)	2 mg (D1-D3)
PFS [months]	2.0	1.3	3.2
Reason for Discontinuation	Progressive disease	Progressive disease	Decreased performance status after infectious complication